Relugolix
Who holds supplier records for Relugolix? 17 organisations hold a current record for Relugolix: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (8), China (6) and Spain (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Relugolix: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/relugolix
Reading the evidence
- 17 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 9 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Relugolix expires 29 Sept 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (17)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Relugolix. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 41612 · latest filing Mar 2025
- Aurisco Pharmaceutical Co.,ltdChina Company GMP cert on recordActive DMF 38488 · latest filing Jul 2024
- BDR LIFESCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 40209 · latest filing Jul 2024
- BEIJING HOPE PHARMACEUTICAL CO LTDActive DMF 40544 · latest filing Sept 2024
- Biocon LimitedIndiaActive DMF 43776 · latest filing Mar 2026
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 39161 · latest filing Dec 2023
- Cipla LimitedIndia Company GMP cert on recordActive DMF 39608 · latest filing Mar 2024
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 39507 · latest filing Mar 2024
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 40410 · latest filing Sept 2024
- Jiangsu Lianhuan Pharmaceutical Co.,Ltd.ChinaActive DMF 42551 · latest filing Sept 2025
- LEE PHARMA LTDIndia Company GMP cert on recordActive DMF 37365 · latest filing Sept 2022
- MOEHS IBERICA SLSpainActive DMF 37795 · latest filing Dec 2022
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 40461 · latest filing Sept 2024
- Porton Pharma Solutions Ltd.ChinaActive DMF 39995 · latest filing Jun 2024
- Shandong Loncom Pharmaceutical Co.,ltd.ChinaActive DMF 43757 · latest filing Mar 2026
- WEINAN MANARECO PHARMACEUTICAL CO LTDActive DMF 42313 · latest filing Jul 2025
- Zhejiang Jingsheng Pharmaceutical Co., Ltd.ChinaActive DMF 43563 · latest filing Apr 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Relugolix are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- India · Inactive DMF 40244 · filed Jul 2024
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Relugolix). The latest listed patent expires 29 Sept 2037. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Relugolix is an orally-active non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of hormone-sensitive conditions such as prostate cancer and uterine fibroids. It works by reducing the levels of certain hormones in the body, thus inhibiting tumor growth in hormone-dependent cancers.
Chemical identity
- IUPAC name
- 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- Canonical SMILES
- CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
- InChIKey
- AOMXMOCNKJTRQP-UHFFFAOYSA-N
- Synonyms
- Orgovyx API, myfembree component relugolix, orgovyx, tak-385
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Gonadotropin Releasing Hormone Receptor Antagonist
- Mechanism of action
- Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 3A Inducers; Gonadotropin Releasing Hormone Receptor Antagonists; P-Glycoprotein Inhibitors
- Physiologic effect
- Decreased GnRH Secretion
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Relugolix?
17 organisations hold an active US FDA Type II Drug Master File or a CEP for Relugolix: ALIVUS LIFE SCIENCES LTD (India), Aurisco Pharmaceutical Co.,ltd (China), BDR LIFESCIENCES PRIVATE LIMITED (India), BEIJING HOPE PHARMACEUTICAL CO LTD, Biocon Limited (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), Cipla Limited (India) and Dr. Reddy's Laboratories Ltd. (India), and 9 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Relugolix Drug Master Files are active?
ALIVUS LIFE SCIENCES LTD (DMF 41612), Aurisco Pharmaceutical Co.,ltd (DMF 38488), BDR LIFESCIENCES PRIVATE LIMITED (DMF 40209), BEIJING HOPE PHARMACEUTICAL CO LTD (DMF 40544), Biocon Limited (DMF 43776), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 39161), Cipla Limited (DMF 39608) and Dr. Reddy's Laboratories Ltd. (DMF 39507) and 9 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Relugolix records mean?
1 organisation has only inactive Type II DMFs for Relugolix. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Relugolix?
Yes. The latest patent listed for an approved US product containing Relugolix expires 29 Sept 2037, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Relugolix supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Relugolix?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.